letrozole and tomoxiprole

letrozole has been researched along with tomoxiprole in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	1 (100.00)	2.80

Authors

Authors	Studies
Adamo, B; Carey, LA; Chic, N; Conte, B; Conte, P; Cortes, J; Dieci, MV; Fernandez-Martinez, A; Galvan, P; Gavila, J; Griguolo, G; Guarnieri, V; Llombart, A; Muñoz, M; Oliveira, M; Paré, L; Pascual, T; Pernas, S; Perou, CM; Prat, A; Tanioka, M; Vidal, M; Villagrasa, P	1

Other Studies

1 other study(ies) available for letrozole and tomoxiprole

Article	Year
Independent Validation of the PAM50-Based Chemo-Endocrine Score (CES) in Hormone Receptor-Positive HER2-Positive Breast Cancer Treated with Neoadjuvant Anti-HER2-Based Therapy. Clinical cancer research : an official journal of the American Association for Cancer Research, 2021, 06-01, Volume: 27, Issue:11 Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Female; Humans; Imidazoles; Letrozole; Middle Aged; Molecular Targeted Therapy; Neoadjuvant Therapy; Prognosis; Receptor, ErbB-2; Trastuzumab; Treatment Outcome	2021

Article

Year

Independent Validation of the PAM50-Based Chemo-Endocrine Score (CES) in Hormone Receptor-Positive HER2-Positive Breast Cancer Treated with Neoadjuvant Anti-HER2-Based Therapy.

Clinical cancer research : an official journal of the American Association for Cancer Research, 2021, 06-01, Volume: 27, Issue:11

Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Female; Humans; Imidazoles; Letrozole; Middle Aged; Molecular Targeted Therapy; Neoadjuvant Therapy; Prognosis; Receptor, ErbB-2; Trastuzumab; Treatment Outcome

2021